Initiatives for Increased Sales
Strategic shift in focus: The company has more clearly shifted its focus towards sales growth. Resources are now more heavily allocated to sales and marketing activities for the existing portfolio of intimate self-care products, while fewer resources are dedicated to the development of future products.
Established partnerships: The emphasis is on maximizing the leverage of existing partnerships through volume increases and the broadening of the product offering to take advantage of already established channels. At the same time, initiatives have been taken to expand distribution in
Increased presence in America: During 2023, America, primarily the
Expanding distribution in
Measures for Cost Efficiency
A thorough review of the company's overhead costs has resulted in measures that will gradually reduce these significantly. The full effect of the initiatives is expected around the turn of the year.
Reducing the organization: Staff and the board have been reduced after careful consideration to streamline the company's resources while maintaining the capacity to increase revenue.
Reduced product development: The plan to develop and launch ten products in 2024 has been reduced to four, freeing up resources for sales and marketing activities.
Subsidiary Lune: In 2023, Peptonic's subsidiary Lune generated sales of 11.3 MSEK, with a negative operating result of -4 MSEK. Despite several initiatives to create growth and profitability, increased competition has contributed to a continued decline in sales and an increase in losses. Lune filed for bankruptcy in the spring of 2024. The winding down of Lune will reduce Peptonic's overhead costs and improve operating results.
In summary, CEO
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic
Central to the growth strategy is the geographical expansion of VagiVital and Verniva through local partners. Peptonic Medical also intends to continuously broaden the company's product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.
The company is headquartered in Stockholm, Sweden, and has subsidiaries
https://news.cision.com/peptonic-medical-ab/r/peptonic-medical-provides-an-operational-update-after-the-first-120-days-with-new-ceo,c3998574
(c) 2024 Cision. All rights reserved., source